Abstract
Treatments for renal cell carcinoma, while promising, are still limited by toxicity and cost. In the hopes of finding a novel compound or combination, we developed a plasmid containing the genes for interleukin-2 (IL-2) and soluble vascular endothelial growth factor receptor 2 (msFlk1). The plasmid, p2CMVIL2/msFlk1, demonstrated similar in vitro transgene expression of IL-2 or msFlk1 compared to their single-agent counterparts. Subcutaneous tumor growth was significantly inhibited in the p2CMVIL2/msFlk1 group when delivered locally by the non-viral water soluble polymer, WSLP and exhibited a 50% increase in survival over glucose and single-agent controls. In vivo experimentation demonstrated that WSLP/msFlk1 decreased microvessel density in pCMVmsFlk1 and p2CMVIL2/msFlk1 treated groups. Furthermore, tumor-infiltrating lymphocytes expressing CD45RO and CD68 were increased within the tumor microenvironment upon p2CMVIL2/msFlk1 treatment. To determine the effects of p2CMVIL2/msFlk1 in an experimental RENCA lung metastases model, therapeutic DNA was delivered systemically following complexation with the angiogenic endothelial-targeting polymer PEI-g-PEG-RGD. The p2CMVIL2/msFlk1 treatment significantly reduced metastases by 56% over single-agent therapy and increased survival proportions by 50% over all groups. Our work clearly demonstrates that non-viral delivery of p2CMVIL2/msFlk1 can inhibit RENCA growth in a synergistic manner and may represent a new treatment for renal carcinoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sternberg CN . Metastatic renal cell cancer treatments. Drugs Today (Barc) 2003; 39 (Suppl C): 39–59.
Fisher RI, Rosenberg SA, Fyfe G . Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (Suppl 1): S55–S57.
Robson CJ, Churchill BM, Anderson W . The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297–301.
McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133–141.
Mier JW, Aronson FR, Numerof RP, Vachino G, Atkins MB . Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res 1988; 7: 459–476.
Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007; 51: 168–173.
Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20: 3792–3803.
Kisker O, Becker CM, Prox D, Fannon M, D’Amato R, Flynn E et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669–7674.
Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S et al. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer 2004; 101: 2557–2566.
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415–419.
Mahato RI, Lee M, Han S, Maheshwari A, Kim SW . Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol Ther 2001; 4: 130–138.
Amato RJ, Morgan M, Rawat A . Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer 2006; 106: 1498–1506.
Keke F, Hongyang Z, Hui Q, Jixiao L, Jian C . A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer. Cancer Biother Radiopharm 2004; 19: 649–657.
Schmitz V, Tirado-Ledo L, Raskopf E, Rabe C, Wernert N, Wang L et al. Effective antitumour mono- and combination therapy by gene delivery of angiostatin-like molecule and interleukin-12 in a murine hepatoma model. Int J Colorectal Dis 2005; 20: 494–501.
Tai KF, Chen PJ, Chen DS, Hwang LH . Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. J Gene Med 2003; 5: 386–398.
Lee M, Ko KS, Oh S, Kim SW . Prevention of autoimmune insulitis by delivery of a chimeric plasmid encoding interleukin-4 and interleukin-10. J Control Release 2003; 88: 333–342.
Ritchie AW, Chisholm GD . The natural history of renal carcinoma. Semin Oncol 1983; 10: 390–400.
Kim WJ, Yockman JW, Lee M, Jeong JH, Kim YH, Kim SW . Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Control Release 2005; 106: 224–234.
Kim WJ, Yockman JW, Jeong JH, Christensen LV, Lee M, Kim YH et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J Control Release 2006; 114: 381–388.
Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605–4610.
Tseng JF, Farnebo FA, Kisker O, Becker CM, Kuo CJ, Folkman J et al. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery 2002; 132: 857–865.
Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999; 82: 293–301.
Belldegrun A, Muul LM, Rosenberg SA . Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 1988; 48: 206–214.
Marumo K, Ueno M, Muraki J, Baba S, Tazaki H . Augmentation of cell-mediated cytotoxicity against renal carcinoma cells by recombinant interleukin 2. Urology 1987; 30: 327–332.
Roth MD . Interleukin 2 induces the expression of CD45RO and the memory phenotype by CD45RA+ peripheral blood lymphocytes. J Exp Med 1994; 179: 857–864.
Akbar AN, Terry L, Timms A, Beverley PC, Janossy G . Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J Immunol 1988; 140: 2171–2178.
Norton AJ, Ramsay AD, Smith SH, Beverley PC, Isaacson PG . Monoclonal antibody (UCHL1) that recognises normal and neoplastic T cells in routinely fixed tissues. J Clin Pathol 1986; 39: 399–405.
Bukur J, Malenica B, Huber C, Seliger B . Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol 2003; 64: 1081–1092.
Bukur J, Seliger B . The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies. Semin Cancer Biol 2003; 13: 353–359.
Acknowledgements
This work was supported by National Institute of Health Grant CA107070. Special thanks to Sheryl Tripp and ARUP for tissue staining.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yockman, J., Kim, W., Chang, CW. et al. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma. Gene Ther 14, 1399–1405 (2007). https://doi.org/10.1038/sj.gt.3302999
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302999
This article is cited by
-
A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy
Cancer Gene Therapy (2012)
-
Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice
Cancer Immunology, Immunotherapy (2010)
-
Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct
Gene Therapy (2009)